Beyond Air Inc
beyondair.netBeyond Air Inc (NASDAQ: XAIR) is a commercial-stage medical device and biopharmaceutical company that develops nitric oxide generators and delivery systems for therapeutic use. Its revenue model centers on the sale and commercialization of the LungFit® platform, a device that generates nitric oxide from ambient air and delivers it directly to patients or via ventilator. The company's first approved product, LungFit® PH, received FDA premarket approval in June 2022 and is indicated for persistent pulmonary hypertension of the newborn (PPHN) in term and near-term neonates (greater than 34 weeks gestation). Beyond Air commenced U.S. marketing of LungFit® PH in July 2022. The company also operates two preclinical-stage pharmaceutical subsidiaries, Beyond Cancer and NeuroNos, engaged in early-stage research. The PPHN market is described in the FY2025 10-K as highly competitive, with market acceptance at an appropriate price proving difficult. No revenue figures or customer concentration data are disclosed in the available filing excerpts.
Products & Services
LungFit® PH: FDA-approved (June 2022) nitric oxide generator and delivery system for PPHN in term and near-term neonates; capable of generating NO up to 400 parts per million (ppm), delivering continuously or for fixed durations at variable flow rates with dose titration capability. Beyond Cancer and NeuroNos: preclinical-stage pharmaceutical research subsidiaries (as of 10-K filed 2025-06-20).
Revenue Model
Product sales from commercialization of the LungFit® PH medical device in the United States, commenced July 2022. No subscription, royalty, or licensing revenue model is described in the available filing excerpts.
Customers & Markets
Hospital neonatal units treating persistent pulmonary hypertension of the newborn (PPHN). End-market is term and near-term neonates (greater than 34 weeks gestation) with hypoxic respiratory failure. No customer concentration data disclosed in available filing excerpts.
Geographic Exposure
United States commercial market for LungFit® PH as of July 2022. No additional geographic revenue data disclosed in available filing excerpts.
Financial Snapshot
Loading...
